Pravastatin inhibits fibrinogen-and FDP-induced inflammatory response via reducing the production of IL-6, TNF-α and iNOS in vascular smooth muscle cells

Molecular Medicine Reports

Volumn 12, Issue 4, 2015, Pages 6145-6151

  Lu, Peipei ^a   Liu, Juntian ^a   Pang, Xiaoming ^a  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Atherosclerosis; Fibrinogen; Inflammatory cytokine; Pravastatin; Vascular smooth muscle cells

Indexed keywords

FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; MESSENGER RNA; PRAVASTATIN; TUMOR NECROSIS FACTOR ALPHA; NOS2 PROTEIN, RAT;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOFLUORESCENCE; INFLAMMATION; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASCULAR SMOOTH MUSCLE CELL; VASCULITIS; ANIMAL; CELL LINE; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; SMOOTH MUSCLE CELL; SPRAGUE DAWLEY RAT; VASCULAR SMOOTH MUSCLE;

ANIMALS; ATHEROSCLEROSIS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; INFLAMMATION; INTERLEUKIN-6; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NITRIC OXIDE SYNTHASE TYPE II; PRAVASTATIN; RATS, SPRAGUE-DAWLEY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84940540459     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.4149     Document Type: Article

References (37)

1. Hansson GK: Infammation, atherosclerosis and coronary artery disease. N Engl J Med 352: 1685-1695, 2005.
2. Libby P: Infammation in atherosclerosis. Nature 420: 868-874, 2002.
3. Bermudez EA, Rifai N, Buring J, Manson JE and Ridker PM: Interrelationships among circulating interleukin-6, C-reactive protein and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol 22: 1668-1673, 2002.
4. Lind L: Circulating markers of infammation and atherosclerosis. Atherosclerosis 169: 203-214, 2003.
5. Huber SA, Sakkinen P, Conze D, Hardin N and Tracy R: Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol 19: 2364-2367, 1999.
6. Ross R: Atherosclerosis-an inflammatory disease. N Engl J Med 340: 115-126, 1999.
7. Lominadze D, Dean WL, Tyagi SC and Roberts AM: Mechanisms of fbrinogen-induced microvascular dysfunction during cardiovascular disease. Acta Physiol (Oxf) 198: 1-13, 2010.
8. Sen U, Tyagi N, Patibandla PK, Dean WL, Tyagi SC, Roberts A M and Lominadze D: Fibrinogen-induced endothelin-1 production from endothelial cells. Am J Physiol Cell Physiol 296: C840-C847, 2009.
9. Szaba FM and Smiley ST: Roles for thrombin and fbrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood 99: 1053-1059, 2002.
10. Robson SC, Shephard EG and Kirsch RE: Fibrin degradation product D-dimer induces the synthesis and release of biologically active IL-lbeta, IL-6 and plasminogen activator inhibitors from monocytes in vitro. Br J Haematol 86: 322-326, 1994.
11. Kuhns DB, Nelson EL, Alvord WG and Gallin JI: Fibrinogen induces IL-8 synthesis in human neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine or leukotriene B(4). J Immunol 167: 2869-2878, 2001.
12. Tsakadze NL, Zhao Z and D'Souza SE: Interaction of intercellular adhesion molecule-1 with fbrinogen. Trends Cardiovasc Med 12: 101-108, 2002.
13. Mosesson MW: Fibrinogen and fbrin structure and functions. J Thromb Haemost 3: 1894-1904, 2005.
14. Tyagi N, Roberts AM, Dean WL, Tyagi SC and Lominadze D: Fibrinogen induces endothelial cell permeability. Mol Cell Biochem 307: 13-22, 2008.
15. Patibandla PK, Tyagi N, Dean WL, Tyagi SC, Roberts AM and Lominadze D: Fibrinogen induces alterations of endothelial cell tight junction proteins. J Cell Physiol 221: 195-203, 2009.
16. Rauch BH, Müschenborn B, Braun M, Weber AA and Schrör K: ICAM-1 and p38 MAPK mediate fbrinogen-induced migration of human vascular smooth muscle cells. Eur J Pharmacol 577: 54-57, 2007.
17. Naito M, Stirk CM, Smith EB and Thompson WD: Smooth muscle cell outgrowth stimulated by fbrin degradation products: The potential role of fbrin fragment E in restenosis and athero-genesis. Thromb Res 98: 165-174, 2000.
18. Hicks RC, Golledge J, Mir-Hasseine R and Powell JT: Vasoactive effects of fbrinogen on saphen ousvein. Nature 379: 818-820, 1996.
19. Guo F, Liu JT, Wang CJ, Liu N and Lu PP: Fibrinogen, fbrin and FDP induce C-reactive protein generation in rat vascular smooth muscle cells: Pro-infammatory effect on atherosclerosis. Biochem Biophy Res Commun 390: 942-946, 2009.
20. Lu PP, Liu JT, Liu N, Guo F, Ji YY and Pang X: Pro-infammatory effect of fbrinogen and FDP on vascular smooth muscle cells by IL-6, TNF-α and iNOS. Life Sci 88: 839-845, 2011.
21. Veillard NR and Mach F: Statins: The new aspirin? Cell Mol Life Sci 59: 1771-1786, 2002.
22. Gaugler MH, Vereycken-Holler V, Squiban C, Vandamme M, Vozenin-Brotons MC and Benderitter M: Pravastatin limits endothelial activation after irradiation and decreases the resulting inflammatory and thrombotic responses. Radiat Res 163: 479-487, 2005.
23. Hadrava V, Tremblay J and Hamet P: Abnormalities in growth characteristics of aortic smooth muscle cells in spontaneously hypertensive rats. Hypertension 13: 589-597, 1989.
24. Takemoto M and Liao JK: Pleiotropic effects of 3-hydroxy-3-meth-ylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 21: 1712-1719, 2001.
25. Tedgui A and Mallat Z: Cytokines in atherosclewrosis: Pathogenic and regulatory pathways. Physiol Rev 86: 515-581, 2006.
26. Yudkin JS, Kumari M, Humphries SE and Mohamed-Ali V: Inflammation, obesity, stress and coronary heart disease: Is interleukin-6 the link? Atherosclerosis 148: 209-214, 2000.
27. Kosmala W, Przewlocka-Kosmala M and Mazurek W: Proinfammatory cytokines and myocardial viability in patients after acute myoca rdial in fa rction. Int J Cardiol 101: 449-456, 2005.
28. Buttery LD, Springall DR, Chester AH, Evans TJ, Standfeld EN, Parums DV, Yacoub MH and Polak JM: Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. Lab Invest 75: 77-85, 1996.
29. Luoma JS, Strålin P, Marklund SL, Hiltunen TP, Särkioja T and Ylä-Herttuala S: Expression of extracellular SOD and iNOS in macrophages and smooth muscle cells in human and rabbit atherosclerotic lesions: Colocalization with epitopes characteristic of oxidized LDL and peroxynitrite-modified proteins. Arterioscler Thromb Vasc Biol 18: 157-167, 1998.
30. Radomski MW and Salas E: Nitric oxide-biological mediator, modulator and factor of injury: its role in the pathogenesis of atherosclerosis. Atherosclerosis 118 (Suppl): S69-S80, 1995.
31. Smith EB, Thompson WD, Crosbie L and Stirk CM: Fibrinogen/fbrin in atherogenesis. Eur J Epidemiol 8 (Suppl 1): 83-87, 1992.
32. Perez RL and Roman J: Fibrin enhances the expression of IL-lbeta by human peripheral blood mononuclear cells. Implications in pulmonary inflammation. J Immunol 154: 1879-1887, 1995.
33. Lin R, Liu J, Peng N, Yang G, Gan W and Wang W: Lovastatin reduces nuclear factor kappaB activation induced by C-reactive protein in human vascular endothelial cells. Biol Pharm Bull 28: 1630-1634, 2005.
34. Peng N, Liu JT, Gao DF, Lin R and Li R: Angiotensin II-induced C-reactive protein generation: Infammatory role of vascular smooth muscle cells in atherosclerosis. Atherosclerosis 193: 292-298, 2007.
35. Wang C, Liu J, Guo F, Ji Y and Liu N: Endothelin-1 induces the expression of C-reactive protein in rat vascular smooth muscle cells. Biochem Biophys Res Commun 389: 537-542, 2009.
36. Han C, Liu J, Liu X and Li M: Angiotensin induces C-reactive protein expression through ERK1/2 and JNK signaling in human aortic endothelial cells. Atherosclerosis 212: 206-212, 2010.
37. Li M, Liu J, Han C, Wang B, Pang X and Mao J: Angiotensin II induces the expression of c-reactive protein via MAPK-dependent signal pathway in U937 macrophages. Cell Physiol Biochem 27: 63-70, 2011.